What is Phenomix Sciences?
Phenomix Sciences is at the vanguard of personalized healthcare, specializing in AI-driven precision obesity medicine. The company leverages a sophisticated integration of genetic, clinical, and biomarker data to tailor treatment strategies, aiming to optimize patient outcomes. Its proprietary MyPhenome Test is engineered to pinpoint the underlying causes of obesity, thereby guiding clinicians toward the most effective therapeutic interventions. By providing data-driven insights, Phenomix empowers healthcare providers to deliver timely and appropriate care, which is crucial for reducing healthcare costs and enhancing patient adherence to treatment plans. The company's focus on transforming obesity care through advanced analytics positions it as a key player in the rapidly evolving landscape of personalized medicine.
How much funding has Phenomix Sciences raised?
Phenomix Sciences has raised a total of $7.8M across 2 funding rounds:
Grant
$2.3M
Series A
$5.5M
Grant (2024): $2.3M with participation from National Institutes of Health
Series A (2024): $5.5M led by Labcorp, Dexcom, and Health2047
Key Investors in Phenomix Sciences
National Institutes of Health
The National Institutes of Health (NIH) is a primary agency of the U.S. Department of Health and Human Services, dedicated to biomedical and health-related research. Its involvement suggests a strong scientific validation and potential for future research collaborations.
Labcorp
Labcorp is a leading global life sciences company providing vital information for doctors, hospitals, and researchers. Their investment indicates a strategic alignment with diagnostic advancements and the integration of laboratory services into precision medicine.
Dexcom
Dexcom is a prominent medical technology company focused on continuous glucose monitoring systems. Their participation suggests an interest in synergistic technologies that enhance chronic disease management and patient monitoring.
What's next for Phenomix Sciences?
The recent major strategic investment signals a critical growth phase for Phenomix Sciences, likely enabling the company to scale its operations, expand its research and development capabilities, and broaden its market reach. This capital will be instrumental in further refining its AI algorithms and expanding the clinical utility of the MyPhenome Test. Phenomix is poised to solidify its position as a leader in precision obesity medicine, driving innovation in how obesity is understood, diagnosed, and treated. The company's trajectory suggests a strong focus on strategic partnerships and clinical validation to further integrate its solutions into mainstream healthcare.
See full Phenomix Sciences company page
